# SARS-CoV-2 nsp14-IN-2

| | |
|---|---|
| **Cat. No.:** | HY-150681 |
| **CAS No.:** | 2816165-16-7 |
| **Molecular Formula:** | $C_{21}H_{21}N_5O_5S$ |
| **Molecular Weight:** | 455.49 |
| **Target:** | SARS-CoV |
| **Pathway:** | Anti-infection |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | SARS-CoV-2 nsp14-IN-2 is a potent SARS-CoV-2 Nsp14 methyltransferase inhibitor with an $IC_{50}$ value of 0.093 μM. SARS-CoV-2 nsp14-IN-2 shows antiviral activity. SARS-CoV-2 nsp14-IN-2 shows plasma and liver S9 stability. SARS-CoV-2 nsp14-IN-2 has the potential for the research of COVID-19[1]. |
| **$IC_{50}$ & Target** | $IC_{50}$: 0.093 μM (SARS-CoV-2 Nsp14 methyltransferase)[1]. |
| **In Vitro** | SARS-CoV-2 nsp14-IN-2 (compound 10) (0-100 μM) shows antiviral activity with an $EC_{50}$ value of 0.72 μM and $CC_{50}$ value of >100 μM[1].<br>SARS-CoV-2 nsp14-IN-2 (24 h) shows plasma stability with $t_{1/2}$s of >24, >24 h for human and mouse, respectively[1].<br>SARS-CoV-2 nsp14-IN-2 (45 min) shows liver S9 stability with $t_{1/2}$ values of 842 min and >45 min in Phase I and phase II in human liver, respectively; and $t_{1/2}$ values of 28.9 min and >45 min in Phase I and phase II in mouse liver, respectively[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## REFERENCES

[1]. Eunkyung Jung et al. Bisubstate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase. ACS Med. Chem. Lett. 2022.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA